A new, rapid point-of-care test for group B streptococcus colonization (Cepheid GenXpert), was recently evaluated in a multicenter trial and reported at the annual meeting of the Infectious Disease Society for Obstetrics/Gynecology (IDSOG), held in Monterey, Calif. Dr. Rodney Edwards from the University of Florida reported that the sensitivity of the new test was 91% and the specificity was 96%, used in both antepartum and intrapartum clinical settings. Intrapartum tests were performed by Labor and Delivery nurses after a short training session. Using real-time PCR technology, results are usually available in 70 minutes, which should be timely enough to begin antibiotic prophylaxis for those mothers found to be colonized. Costs of the new technology, which has just been approved by the FDA, vary by locality, but average around $40 per specimen run.
A new, rapid point-of-care test for group B streptococcus colonization (Cepheid GenXpert), was recently evaluated in a multicenter trial and reported at the annual meeting of the Infectious Disease Society for Obstetrics/Gynecology (IDSOG), held in Monterey, Calif. Dr. Rodney Edwards from the University of Florida reported that the sensitivity of the new test was 91% and the specificity was 96%, used in both antepartum and intrapartum clinical settings. Intrapartum tests were performed by Labor and Delivery nurses after a short training session. Using real-time PCR technology, results are usually available in 70 minutes, which should be timely enough to begin antibiotic prophylaxis for those mothers found to be colonized. Costs of the new technology, which has just been approved by the FDA, vary by locality, but average around $40 per specimen run.
Long-term mortality risks for women with adverse pregnancy outcomes
April 19th 2024A recent study revealed that women who experience major adverse pregnancy outcomes face heightened long-term mortality risks, shedding light on the need for comprehensive understanding and preventative measures in women's health.
Read More
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More